English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Increased antimicrobial resistance, including multi-drug resistance, has been reported in Klebsiella spp. from intensive care units (ICUs), limiting treatment options in this setting. Using 2012-2016 North America and Latin America data from the Tigecycline Evaluation Surveillance Trial (TEST) program, susceptibility of Klebsiella spp. was analyzed according to patient location. Background: Klebsiella spp. are one of the most frequently isolated gram-negative pathogens infecting seriously ill patients in intensive care units. Increasing resistance mechanisms associated with this species group has led to the inclusion of K. pneumoniae as a member of the ESKAPE pathogens as determined by the Infectious Disease Society of America (IDSA). Regional variations of susceptibility to several classes of antimicrobial agents can provide guidance when selecting appropriate antimicrobial therapy. Data from Tigecycline Evaluation Surveillance Trial (TEST) program 2012-2016 were used to determine antimicrobial susceptibility patterns in Klebsiella spp.in patients in ICUs and non-ICUs in both Latin America (LA) and North America (NA). Methods: Klebsiella spp. isolates were identified locally and antimicrobial susceptibility testing was done using broth microdilution according to CLSI guidelines at each participating institution in NA and LA. CLSI or FDA (tigecycline) breakpoint criteria were applied to define susceptibility status. Results: Susceptibility by region and patient location are shown in the following table.

In Vitro Susceptibility Profiles of Klebsiella spp. Isolated from ICU and non-ICU Wards in North and Latin America (TEST Program 2012–2016)